1. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia. (11th May 2020) Authors: Zabkiewicz, Joanna; Lazenby, Michelle; Edwards, Gareth; Bygrave, Ceri A.; Omidvar, Nader; Zhuang, Lihui; Knapper, Steve; Guy, Carol; Hills, Robert K.; Burnett, Alan K.; Alvares, Caroline L. Journal: British journal of haematology Issue: Volume 191:Number 2(2020) Page Start: 231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The HSP90 inhibitor NVP‐AUY922‐AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. (29th January 2013) Authors: Walsby, Elisabeth J.; Lazenby, Michelle; Pepper, Chris J.; Knapper, Steven; Burnett, Alan K. Journal: British journal of haematology Issue: Volume 161:Number 1(2013:Apr.) Page Start: 57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗